Revelation Biosciences Forms Five-Member Advisory Board for Phase 2/3 Gemini AKI Trial
Revelation Biosciences formed an AKI Advisory Board for its Phase 2/3 Gemini trial, enlisting five leading nephrologists and critical care physicians to guide clinical strategy. Led by Laurence Busse, MD, MBA, FCCM, the board will set study design and monitor progress to address unmet needs in acute kidney injury treatment.
1. AKI Advisory Board Formation
Revelation Biosciences has formed an Acute Kidney Injury Advisory Board to guide its Phase 2/3 clinical trial of Gemini. The board will advise on study design, patient selection criteria and clinical strategy to accelerate development of the company’s novel immune-modulating therapy for AKI.
2. Leadership and Expertise
The five-member panel is chaired by Principal Investigator Laurence Busse, MD, MBA, FCCM, and includes experts in nephrology and critical care such as Sean Bagshaw and Javier Neyra. Members bring experience from leading academic and clinical institutions across North America in AKI research and clinical trials.
3. Implications for Gemini Trial
By assembling this advisory group, Revelation aims to address the substantial unmet medical need in acute kidney injury and optimize trial protocols. Board oversight is expected to enhance data quality, patient safety and study efficiency ahead of key efficacy readouts.